AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Tuberous Sclerosis Complex

Recent research efforts aimed at curing Tuberous Sclerosis Complex.

Last updated

Tuberous Sclerosis Complex

Overview

Tuberous Sclerosis Complex (TSC) is a lifelong genetic condition caused by disease-causing changes in either the TSC1 or TSC2 gene. These genes normally restrain a cell-growth pathway called mTOR; when that restraint is weakened, benign growths and developmental abnormalities can arise in the brain, kidneys, heart, lungs, skin, and eyes. TSC affects people very differently: some have mainly skin findings, while others develop epilepsy, developmental or behavioral difficulties, kidney angiomyolipomas, lung disease, or brain tumors called subependymal giant cell astrocytomas (SEGAs). Seizures occur in about 80% of affected people, and TSC-associated neuropsychiatric disorders affect more than 90%, making early neurological care especially important. GeneReviews: Tuberous Sclerosis Complex

Prognosis is therefore highly variable and depends on which organs are involved and how effectively complications are monitored and treated. Current care is preventive and multidisciplinary: regular brain, kidney, lung, skin, heart, eye, and developmental surveillance; anti-seizure medicines, dietary therapy, or epilepsy surgery when needed; and mTOR inhibitors such as everolimus or sirolimus for selected tumors, refractory seizures, and other manifestations. These drugs compensate for part of the missing TSC1/TSC2 function but do not repair the underlying genetic change. GeneReviews: Tuberous Sclerosis Complex

Scope of Recent Research (2020–present)

Since 2020, TSC research has become more explicitly “disease-modifying,” with efforts ranging from early seizure prevention and better pathway inhibition to direct replacement or correction of TSC1 and TSC2. The central curative question is whether enough affected cells across the brain and other organs can be safely given a functioning gene—or have their mutation corrected—before irreversible developmental changes occur. Encouraging animal and cell-model results exist, but the field remains preclinical for genetic cures; current human studies are testing earlier and more targeted use of pathway-modifying drugs rather than gene replacement or genome editing. Gene therapy for TSC2 in a mouse model CRISPR correction of TSC2 variants in patient iPSCs Stopping TSC Onset and Progression 2

Major Breakthroughs and Emerging Therapies

The most direct potential cure strategy is gene replacement. In a 2021 mouse study of TSC2-related disease, researchers engineered a shortened but functional version of tuberin, the protein encoded by TSC2, because the full TSC2 coding sequence is too large for a standard adeno-associated virus (AAV) gene-therapy vector. A single intravenous dose of AAV9 carrying this “condensed” tuberin markedly extended survival and reduced brain pathology in a mouse model with Tsc2-deficient brain lesions. This is a major proof of principle, but it is not yet evidence that AAV treatment can safely and durably treat people with TSC, whose disease is genetically and clinically more diverse. Gene therapy for TSC2 in a mouse model

Gene editing is also advancing as a personalized-curative approach. In 2025, investigators used CRISPR-Cas9 with homology-directed repair—a DNA-template-based correction method—to repair two pathogenic TSC2 variants in patient-derived induced pluripotent stem cells (iPSCs). Corrected cell clones showed normalized mTOR-pathway signaling and improvement of disease-associated astrocyte features. The work establishes a valuable platform for testing mutation-specific treatments, but it required editing cells outside the body, screening individual corrected clones, and assessing a limited set of possible unintended edits; it is not an in vivo human therapy. CRISPR correction of TSC2 variants in patient iPSCs

Drug discovery is also expanding beyond direct mTOR inhibition. A 2020 study found that blocking autotaxin, an enzyme that produces the signaling molecule lysophosphatidic acid, suppressed growth of TSC2-null tumor cells and reduced tumorigenesis in preclinical models. More recently, a 2024 study identified suppression of epidermal growth factor receptor (EGFR) signaling as a possible alternative or complementary approach for SEGAs, cortical tubers, and related mTOR-driven brain malformations. These approaches may eventually improve control of particular lesions or reduce reliance on mTOR inhibitors, but neither restores a normal TSC1 or TSC2 gene. Autotaxin inhibition in TSC-associated tumorigenesis EGFR targeting as an alternative TSC strategy

A parallel breakthrough has been the shift toward preventing neurological injury rather than waiting for seizures to become established. In EPISTOP, preventive vigabatrin started after abnormal electroencephalography (EEG) but before clinical seizures reduced the risk of seizures, infantile spasms, and drug-resistant epilepsy by age two in the pooled analysis. However, the later PREVeNT trial did not find improved cognition or lower focal-seizure and drug-resistant-epilepsy rates at 24 months. Together, these results show both the promise and difficulty of changing TSC’s developmental course through very early intervention. EPISTOP preventive-vigabatrin trial PREVeNT trial results

Clinical Trials and Experimental Approaches

The most notable current disease-modification trial is Stopping TSC Onset and Progression 2 (NCT04595513), a Phase I/II open-label study of TAVT-18, a pediatric powder formulation of sirolimus developed by Tavanta Therapeutics. The study enrolls five infants with TSC and evaluates safety, drug exposure, and time to seizure onset through infancy, with developmental outcomes assessed at 24 months. Its aim is to determine whether early mTOR suppression can prevent or delay epilepsy, not to correct the underlying mutation. Stopping TSC Onset and Progression 2

A 2024 Phase I report of preventive sirolimus similarly focused on safety and feasibility in infants with TSC, reflecting growing interest in treating the mTOR abnormality during early brain development. For established refractory focal seizures, everolimus remains the best-developed targeted drug strategy: the Phase III EXIST-3 program and its long-term extension continue to provide efficacy and safety follow-up rather than curative treatment. Preventive sirolimus Phase I study EXIST-3 long-term everolimus study

Methodologies and Scientific Approaches

Researchers use complementary models because no single model captures all of TSC. Conditional mouse models allow investigators to delete Tsc1 or Tsc2 in selected brain cells and then test AAV delivery, survival, lesion burden, and mTOR-pathway biomarkers such as phosphorylated S6. The condensed-tuberin study illustrates how these models can test whole-body vector delivery while measuring whether a replacement protein reaches enough affected cells to change severe neurological disease. Gene therapy for TSC2 in a mouse model

Human models are becoming more precise. Patient-derived iPSCs can be converted into neurons and astrocytes, compared with CRISPR-corrected “isogenic” controls that differ only at the disease variant, and studied for mTOR activity, cell size, metabolism, and electrical properties. Cortical organoids—three-dimensional stem-cell-derived models of early brain development—combined with single-cell RNA sequencing and other “multi-omics” measurements are helping identify which cell types and developmental pathways are disrupted by pathogenic TSC2 variants. CRISPR correction of TSC2 variants in patient iPSCs Longitudinal multi-omics in TSC2 cortical organoids

Leading Institutions and Funding

Academic centers driving translational work include Nationwide Children’s Hospital and The Ohio State University, where patient-derived iPSC gene-correction studies have been conducted; Harvard-affiliated investigators, who have pursued tumor-targeted pathway approaches; and multiple pediatric epilepsy and TSC centers running early-intervention trials. The TSC Alliance supports a broad investigator network, with recent awards addressing cortical-organoid epilepsy models, somatic mosaicism, neurological outcome prediction, RNA splicing in SEGAs, and patient-biosample research. CRISPR correction of TSC2 variants in patient iPSCs TSC Alliance grants and funding

The U.S. Department of Defense Congressionally Directed Medical Research Program’s Tuberous Sclerosis Complex Research Program reported $121 million in total appropriations from fiscal years 2002 through 2024. Its 2025 program summary specifically identifies AAV9 gene replacement in TSC1 and TSC2 animal models, extracellular-vesicle delivery approaches, drug combinations, surgical tools, and behavioral interventions among its translational priorities. DoD TSC Research Program summary

Strengths, Limitations, and Challenges

TSC is unusually well positioned for rational therapy because the causal genes and the central mTOR pathway are known, and mTOR inhibitors already provide clinical proof that targeting this biology can shrink tumors and reduce seizures in some people. The gene-replacement and gene-correction studies go a step further by showing that restoring TSC-gene function can normalize disease biology in mice and patient-derived cells. GeneReviews: Tuberous Sclerosis Complex Gene therapy for TSC2 in a mouse model CRISPR correction of TSC2 variants in patient iPSCs

The main obstacle is delivery. A curative treatment would likely need safe, sufficient, and durable correction or replacement across multiple organs and across diverse cell types in the brain, while avoiding immune reactions, harmful overexpression, unintended editing, and unacceptable cancer risk. TSC also involves many different pathogenic variants, mosaicism in some people, and developmental abnormalities that may begin before diagnosis or treatment. Even effective early seizure prevention may not fully prevent cognitive or behavioral effects, as illustrated by differing EPISTOP and PREVeNT results. Gene therapy for TSC2 in a mouse model EPISTOP preventive-vigabatrin trial PREVeNT trial results

Outlook and Future Directions

A true cure for TSC is not yet close in clinical practice, but the research path is clearer than it was at the beginning of this decade: demonstrate safe delivery of TSC1 or TSC2 function in relevant organs, confirm that corrected cells produce lasting neurological and tumor benefits, and determine how early treatment must begin. The milestones to watch are reproducible large-animal and human-ready AAV studies, improved vectors capable of carrying or reconstructing TSC2, in vivo editing approaches with rigorous safety data, and infant trials showing durable benefits beyond seizure delay. Until then, earlier diagnosis, surveillance, individualized seizure care, and mTOR-targeted treatment remain the practical foundation of improving lives with TSC. Gene therapy for TSC2 in a mouse model Stopping TSC Onset and Progression 2 DoD TSC Research Program summary

References

Don't see your disease? Request a report